Velan Capital Investment Management’s ProQR Therapeutics PRQR Stock Holding History

Velan Capital Investment Management’s Portfolio PRQR Stock Details PRQR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$72.9K	Hold	45,000	–	–	0.05%	48
2025 Q4	$90.9K	Hold	45,000	–	–	0.05%	43
2025 Q3	$95.8K	Hold	45,000	–	–	0.09%	45
2025 Q2	$91.8K	Hold	45,000	–	–	0.09%	36
2025 Q1	$59.9K	Buy	45,000 +4,500	+11%	+$9.58K	0.06%	35
2024 Q4	$107K	Buy	+40,500	New	+$129K	0.09%	25

Other funds holding PRQR

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

PFM

Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

Velan Capital Investment Management's PRQR Position: Q1 2026 in Review

Velan Capital Investment Management held its ProQR Therapeutics (PRQR) position steady in Q1 2026 at 45,000 shares worth $72.9K. The position accounts for 0.05% of the portfolio, ranked #48.

Velan Capital Investment Management first reported a position in PRQR in Q4 2024 and has held it in 6 quarters since. The position peaked at $107K in Q4 2024. 69 funds tracked by Wall St. Rank hold PRQR as of Q1 2026.

Velan Capital Investment Management held 45,000 shares of ProQR Therapeutics worth $72.9K as of Q1 2026.
Velan Capital Investment Management left its ProQR Therapeutics share count unchanged in Q1 2026.
ProQR Therapeutics made up 0.05% of Velan Capital Investment Management's portfolio in Q1 2026, its #48 holding.
Velan Capital Investment Management first reported a position in ProQR Therapeutics in Q4 2024 and has held it in 6 quarters since.
Velan Capital Investment Management's ProQR Therapeutics position peaked at $107K in Q4 2024.
69 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q1 2026.

Based on Velan Capital Investment Management's 13F filing for Q1 2026, filed 15 May 2026.